Molecular Oncology
Volume 3, Issue 5 , Pages 464-468, December 2009

Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus

  • Tuba Esfandyari

      Affiliations

    • The Molecular Medicine Laboratory, Department of Medicine, University of Kansas School of Medicine, 1000 Hixon-Mail Stop: 4037, 3901-Rainbow Blvd., Kansas City, KS 66160, USA
  • ,
  • Ayalew Tefferi

      Affiliations

    • Mayo Clinic Rochester, Rochester, MN, USA
  • ,
  • Anna Szmidt

      Affiliations

    • The Medical University of Vienna, Vienna, Austria
  • ,
  • Tommy Alain

      Affiliations

    • University of Calgary, Cancer Biology Research Group, Calgary, AB, Canada
  • ,
  • Pawel Zwolak

      Affiliations

    • The Medical University of Vienna, Vienna, Austria
  • ,
  • Terra Lasho

      Affiliations

    • Mayo Clinic Rochester, Rochester, MN, USA
  • ,
  • Patrick W. Lee

      Affiliations

    • Dalhousie University, Halifax, NS, Canada
  • ,
  • Faris Farassati

      Affiliations

    • The Molecular Medicine Laboratory, Department of Medicine, University of Kansas School of Medicine, 1000 Hixon-Mail Stop: 4037, 3901-Rainbow Blvd., Kansas City, KS 66160, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 913 945 6823 (office), +1 913 945 6881 (lab); fax: +1 913 945 6923; admin. assistant: +1 913 588 6078.

Received 5 February 2009; received in revised form 16 July 2009; accepted 21 July 2009. published online 05 August 2009.

Abstract 

Overactivation in Ras signaling has been under intensive study as the molecular basis for development of cancer. Such overactivation can occur in the presence or absence of mutations in Ras gene resulting in activation of a series of down-stream effectors such as transcription factors. Different studies have shown the activation of Ras down-stream effectors in non-Hodgkin lymphoma (NHL) although mutations in Ras are not prevalent in this malignancy. Since overactivation in Ras signaling also increases permissiveness of cancer cells to infection by oncolytic versions of herpes simplex virus (e.g. R3616), we were interested in evaluating the value of transcription factors down-stream of Ras as molecular indicators for permissiveness to herpes therapy. In order to accomplish this, and also to assess the permissiveness of lymphoma cells to infection with R3616, we used NHL cell lines Daudi, Jurkat, NC37, Raji, Ramos and ST486. Once the levels of phosphorylation (activation) of extracellular-signal regulated kinase (ERK, a Ras effector pathway) and its down-stream transcription factor ELK were evaluated, Raji and NC37 showed a significant increase in the phosphorylation levels of both molecules while ATF2 (another transcription factor down-stream of p38-kinase pathway) seemed to be activated in all studied cells. Raji and NC37 cells were also most permissive cells to infection with R3616 while their permissiveness was decreased upon treatment of cells with an inhibitor of ELK-DNA binding portraying ERK/ELK as a suitable predictive indicator for selection of cancer cells with increased sensitivity to R3616. This study, therefore, for the first time documents permissiveness of lymphoma cells to oncolytic herpes viruses and introduces ELK as a suitable factor for predicting tumor susceptibility to these novel anticancer agents.

Keywords: Lymphomas, NHL, Herpes, HSV, Gene therapy, Oncolytic Viruses, R3616

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(09)00101-X

doi:10.1016/j.molonc.2009.07.002

Molecular Oncology
Volume 3, Issue 5 , Pages 464-468, December 2009